Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 25, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 27, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-26-012533
Filed / recorded
Feb 27, 2026, 1:31 AM UTC
Added to OQRO
Oct 6, 2026, 4:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BIOMARIN PHARMACEUTICAL INC
Issuer CIK
1048477
Ticker
BMRN
Reporting person
George Eric Davis
Relationship
Officer
Officer title
EVP, Chief Legal Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 25, 2026
Transaction code
A
Shares / units
2,372
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
98,514
Ownership form
Direct
Amendment
No
Footnotes from the filing
Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
